Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.
作者信息
O'Reilly Emily, Casey Deborah, Ibrahim Hisham, McGrath Alice, McHugh Tomás, Vairamani Punitha, Murphy Jill, Plant Barry, Murphy Desmond M
机构信息
Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland.
Health Research Board Clinical Research Facility, University College Cork, Cork, Ireland.
出版信息
J Asthma Allergy. 2022 Jul 11;15:935-937. doi: 10.2147/JAA.S358321. eCollection 2022.
Abstract
摘要
相似文献
1
Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.从奥马珠单抗转换为抗白细胞介素-5治疗的哮喘患者的真实世界临床结局
J Asthma Allergy. 2022 Jul 11;15:935-937. doi: 10.2147/JAA.S358321. eCollection 2022.
2
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.奥马珠单抗治疗重度过敏性哮喘的真实世界疗效：一项观察性研究的荟萃分析。
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2702-2714. doi: 10.1016/j.jaip.2021.01.011. Epub 2021 Jan 21.
3
Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.生物标志物与奥马珠单抗治疗变应性哮喘患者真实世界结局相关性的回顾性研究。
Clin Ther. 2019 Oct;41(10):1956-1971. doi: 10.1016/j.clinthera.2019.07.021. Epub 2019 Sep 25.
4
Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.奥马珠单抗治疗美国中重度未控制的过敏性哮喘的成本效果分析。
Curr Med Res Opin. 2020 Jan;36(1):23-32. doi: 10.1080/03007995.2019.1660539. Epub 2019 Sep 13.
5
Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence.利用真实世界证据评估奥马珠单抗治疗日本重度过敏性哮喘的成本效益。
Value Health Reg Issues. 2022 Jan-Feb;27:41-48. doi: 10.1016/j.vhri.2021.07.013. Epub 2021 Nov 14.
6
Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.奥马珠单抗在儿童和成人重度持续性IgE介导哮喘中的有效性和安全性：埃及人群的一项真实世界观察性研究
J Asthma. 2020 Feb;57(2):160-166. doi: 10.1080/02770903.2018.1553051. Epub 2018 Dec 28.
7
[Clinical experience with omalizumab in patients with severe asthma. Real-world data].[奥马珠单抗治疗重度哮喘患者的临床经验。真实世界数据]
Rev Alerg Mex. 2016 Jul-Sep;63(3):216-26. doi: 10.29262/ram.v63i3.144.
8
Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.真实世界中奥马珠单抗和美泊利单抗治疗的难治性哮喘表型及其临床结局。
Clin Exp Allergy. 2021 Aug;51(8):1019-1032. doi: 10.1111/cea.13882. Epub 2021 May 6.
9
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.奥马珠单抗对生物标志物状态的哮喘患者的有效性：来自 PROSPERO 的证据，一项前瞻性真实世界研究。
J Allergy Clin Immunol Pract. 2019 Jan;7(1):156-164.e1. doi: 10.1016/j.jaip.2018.04.043. Epub 2018 May 22.
10
The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.奥马珠单抗附加疗法对中重度过敏性哮喘患者的真实世界疗效：ASTERIX观察性研究
PLoS One. 2017 Aug 31;12(8):e0183869. doi: 10.1371/journal.pone.0183869. eCollection 2017.
引用本文的文献
1
Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.根据GETE评分在2年时被确定为对奥马珠单抗治疗有反应的日本重度哮喘患者继续接受了长期治疗。
J Asthma Allergy. 2024 Nov 14;17:1173-1186. doi: 10.2147/JAA.S423256. eCollection 2024.
2
Advancing Care in Severe Asthma: The Art of Switching Biologics.推进重症哮喘护理：生物制剂转换的艺术。
Adv Respir Med. 2024 Feb 21;92(2):110-122. doi: 10.3390/arm92020014.
3
Switching Biological Therapies in Severe Asthma.重度哮喘中的生物疗法转换。
Int J Mol Sci. 2023 May 31;24(11):9563. doi: 10.3390/ijms24119563.
4
Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab.从瑞利珠单抗转换为美泊利单抗或贝那利珠单抗的哮喘患者的真实世界临床结局
Front Allergy. 2023 Jan 4;3:1052339. doi: 10.3389/falgy.2022.1052339. eCollection 2022.
本文引用的文献
1
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.全球哮喘倡议 2021 战略：执行摘要和关键变更的理由。
Eur Respir J. 2021 Dec 31;59(1). doi: 10.1183/13993003.02730-2021. Print 2022 Jan.
2
Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.日本重度哮喘患者生物制剂转换的有效性：一项单中心回顾性研究。
J Asthma Allergy. 2021 Jun 3;14:609-618. doi: 10.2147/JAA.S311975. eCollection 2021.
3
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.在未控制的严重嗜酸性粒细胞性哮喘中，从奥马珠单抗转换为美泊利珠单抗的临床和经济后果。
Sci Rep. 2021 Mar 9;11(1):5453. doi: 10.1038/s41598-021-84895-2.
4
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.从奥马珠单抗转换为美泊利珠单抗：来自意大利南部的真实临床经验。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620929231. doi: 10.1177/1753466620929231.
5
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation.美泊利珠单抗治疗奥马珠单抗既往治疗失败患者的疗效：真实世界观察
Allergy. 2019 Dec;74(12):2539-2541. doi: 10.1111/all.13937. Epub 2019 Jul 1.
6
Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab.在奥马珠单抗初始治疗结果为阴性后，贝那利珠单抗治疗过敏性和嗜酸性粒细胞为主型哮喘的疗效
Respirol Case Rep. 2018 Nov 21;7(1):e00388. doi: 10.1002/rcr2.388. eCollection 2019 Jan.
Zotero 插件